Phio Pharmaceuticals Corp. (PHIO)

Market Cap	12.27M +40.4%
Revenue (ttm)	n/a
Net Income	-7.95M
EPS	-2.02
Shares Out	10.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	550,287
Open	1.060
Previous Close	1.070
Day's Range	1.060 - 1.160
52-Week Range	0.813 - 4.190
Beta	0.94
Analysts	Strong Buy
Price Target	10.67 (+835.97%)
Earnings Date	Mar 30, 2026

About PHIO

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also develop...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: PHIO
• Website: https://phiopharma.com

Analyst Summary

According to 3 analysts, the average rating for PHIO stock is "Strong Buy." The 12-month stock price target is $10.67, which is an increase of 835.97% from the latest price.

Price Target

$10.67

(835.97% upside)

Analyst Consensus: Strong Buy